Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Triple Negative Breast Neoplasms 1Thyroid Diseases 1Solid Tumors 1Prostatic Neoplasms 1Neoplasms 1Melanoma 1Lymphoma 1Leukemia, Myeloid, Acute 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Breast Neoplasms 1

Interventions

Paclitaxel 15atezolizumab 11Gemcitabine 11Carboplatin 9pembrolizumab 8Docetaxel 8Bevacizumab 8Irinotecan 7Injections 6Cetuximab 6Capecitabine 6Sunitinib 5Leucovorin 5Fluorouracil 5Cyclophosphamide 5tocilizumab 4pazopanib 4olaparib 4navitoclax 4liposomal doxorubicin 4Topotecan 4Oxaliplatin 4Nivolumab 4Erlotinib Hydrochloride 4temsirolimus 3spartalizumab 3lenvatinib 3fludarabine 3cobimetinib 3Cisplatin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Solid Tumors × tomivosertib × Clear all
NCT03616834 2023-03-22

Tomivosertib (eFT-508) in Combination With PD-1/PD-L1 Inhibitor Therapy

Effector Therapeutics

Phase 2 Completed
39 enrolled
Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡